S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

$3.16
+0.06 (+1.94%)
(As of 02/29/2024 ET)
Today's Range
$3.07
$3.25
50-Day Range
$2.94
$3.90
52-Week Range
$0.95
$4.04
Volume
22,165 shs
Average Volume
20,606 shs
Market Capitalization
$33.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Nephros MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Nephros in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$39,600 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.62 out of 5 stars

Medical Sector

735th out of 958 stocks

Surgical & Medical Instruments Industry

82nd out of 98 stocks


NEPH stock logo

About Nephros Stock (NASDAQ:NEPH)

Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

NEPH Stock Price History

NEPH Stock News Headlines

What Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Nephros Inc NEPH
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Benchmark Co. Keeps Their Hold Rating on Nephros (NEPH)
Breakeven On The Horizon For Nephros, Inc. (NASDAQ:NEPH)
Nephros: Q3 Earnings Insights
Nephros Hires Judy Krandel as Chief Financial Officer
Nephros to Present at LD Micro Main Event XVI
NEPH - Nephros, Inc.
Maxim Group Sticks to Their Buy Rating for Nephros (NEPH)
The Price Is Right For Nephros, Inc. (NASDAQ:NEPH)
See More Headlines
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/29/2024
Next Earnings (Estimated)
3/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NEPH
Employees
27
Year Founded
N/A

Profitability

Net Income
$-7,380,000.00
Pretax Margin
-12.11%

Debt

Sales & Book Value

Annual Sales
$13.54 million
Book Value
$0.86 per share

Miscellaneous

Free Float
9,950,000
Market Cap
$33.13 million
Optionable
Not Optionable
Beta
1.36
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Robert Banks
    President, CEO & Director
  • Ms. Judy F. Krandel C.F.A. (Age 59)
    Chief Financial Officer
  • Mr. Alfred Vargas
    Director of Operations
  • Brianne McGuire
    Director of Brand, Marketing & Business Development
  • Vashone R. Thomas
    Vice President of Quality, Regulatory, & Human Resources
  • Mr. Daron G. Evans M.B.A. (Age 50)
    M.S., Chief Executive Officer of Specialty Renal Products, Inc
    Comp: $300.18k
  • Mr. Greg Lucas
    President of Aether Water Systems
  • Ms. Judy Mazzini
    Controller














NEPH Stock Analysis - Frequently Asked Questions

How have NEPH shares performed in 2024?

Nephros' stock was trading at $3.46 at the start of the year. Since then, NEPH stock has decreased by 8.7% and is now trading at $3.16.
View the best growth stocks for 2024 here
.

Are investors shorting Nephros?

Nephros saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 4,100 shares, a decline of 40.6% from the January 31st total of 6,900 shares. Based on an average daily trading volume, of 30,700 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are sold short.
View Nephros' Short Interest
.

When is Nephros' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our NEPH earnings forecast
.

How were Nephros' earnings last quarter?

Nephros, Inc. (NASDAQ:NEPH) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company earned $2.64 million during the quarter, compared to the consensus estimate of $2.64 million. Nephros had a negative net margin of 13.58% and a negative trailing twelve-month return on equity of 18.72%. During the same period in the prior year, the business earned ($0.12) earnings per share.

Who are Nephros' major shareholders?

Nephros' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wexford Capital LP (35.12%). Insiders that own company stock include Andrew Astor, Robert R Jr Banks, Tom Gwydir and Wesley S Lobo.
View institutional ownership trends
.

How do I buy shares of Nephros?

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NEPH) was last updated on 2/29/2024 by MarketBeat.com Staff